Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

• DOI: 10.1523/jneurosci.21-17-06853.2001
• Publication Date: 2018-04-09T00:15:16Z
• Authors: Erwan Bezard; Sandra Dovero; Caroline Prunier; Paula Ravenscroft; Sylvie Chalon; Denis Guilloteau; Alan R. Crossman; Bernard Bioulac; Jonathan M. Brotchie; Christian E. Gross
• Keywords: 0301 basic medicine; Dopamine; metabolism: Tyrosine 3-Monooxygenase; Cell Count; Binding, Competitive; Drug Administration Schedule; 03 medical and health sciences; chemistry: Putamen; Animals; Support, Non-U.S. Gov't; Dopamine Plasma Membrane Transport Proteins; Membrane Glycoproteins; Behavior, Animal; drug effects: Corpus Striatum; analysis: Carrier Proteins; analysis: Homovanillic Acid; analysis: Dopamine; Membrane Transport Proteins; Homovanillic Acid; chemistry: Caudate Nucleus; analysis: 3,4-Dihydroxyphenylacetic Acid; drug effects: Motor Activity; Corpus Striatum; chemically induced: Parkinson Disease, Secondary; Disease Models, Animal; Macaca fascicularis; drug effects: Substantia Nigra; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Disease Progression; 3,4-Dihydroxyphenylacetic Acid; Autoradiography; Female; metabolism: Neurons; metabolism: Receptors, Dopamine D2; Caudate Nucleus; Carrier Proteins; drug effects: Behavior, Animal

The concept of a threshold of dopamine (DA) depletion for onset of Parkinson's disease symptoms, although widely accepted, has, to date, not been determined experimentally in nonhuman primates in which a more rigorous definition of the mechanisms responsible for the threshold effect might be obtained. The present study was thus designed to determine (1) the relationship between Parkinsonian symptom appearance and level of degeneration of the nigrostriatal pathway and (2) the concomitant presynaptic and postsynaptic striatal response to the denervation, in monkeys treated chronically with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine according to a regimen that produces a progressive Parkinsonian state. The kinetics of the nigrostriatal degeneration described allow the determination of the critical thresholds associated to symptom appearance, these were a loss of 43.2% of tyrosine hydroxylase-immunopositive neurons at the nigral level and losses of 80.3 and 81.6% DA transporter binding and DA content, respectively, at the striatal level. Our data argue against the concept that an increase in DA metabolism could act as an efficient adaptive mechanism early in the disease progress. Surprisingly, the D(2)-like DA receptor binding showed a biphasic regulation in relation to the level of striatal dopaminergic denervation, i.e., an initial decrease in the presymptomatic period was followed by an upregulation of postsynaptic receptors commencing when striatal dopaminergic homeostasis is broken. Further in vivo follow-up of the kinetics of striatal denervation in this, and similar, experimental models is now needed with a view to developing early diagnosis tools and symptomatic therapies that might enhance endogenous compensatory mechanisms.